troglitazone has been researched along with Lung Diseases, Interstitial in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Koshida, H | 1 |
| Shibata, K | 1 |
| Kametani, T | 1 |
1 other study available for troglitazone and Lung Diseases, Interstitial
| Article | Year |
|---|---|
Pleuropulmonary disease in a man with diabetes who was treated with troglitazone.
Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lung Diseases, Interstitial; Male; | 1998 |